SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (7184)9/5/1998 8:49:00 AM
From: Robert K.  Respond to of 17367
 
To further drive home the point of cytokine effects of BPI>>>>>>>>>
>>http://www.med.uni-muenchen.de/immuno/ziegler/MonoMac/MM6oth019.html

>Ask yourselves this. How many other sepsis drugs failed that tried to
affect just one cytokine or whatever. TNF, IL-1 etc....
You know anti-TNF monoclonals are finding use NOW.
And they only target TNF. Hmmmmmmmm.
Cascade, cocktail, Hmmmmmm.



To: Bluegreen who wrote (7184)9/5/1998 12:01:00 PM
From: aknahow  Read Replies (1) | Respond to of 17367
 
Think I ran out of paste. No there was some left. Note the oral availability of the antifungal peptide XMP. Does that mean they will need to put an I.V. down the patients mouth? Seems like another big problem for XOMA that the Yahooligans can explore. <g>

Roger Little, Ph.D., "XMP Antifungal Peptides Demonstrate Enhanced Selectivity
and Oral Availability"



HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News